or Email Us
Generously supported in part by Welcome Back Veterans (WBV), an initiative of the McCormick Foundation and Major League Baseball.
Home Base Program clinicians and researchers are engaged in exciting national research to develop better understanding and treatment of post traumatic stress (PTSD) and traumatic brain injury (TBI). This research may lead to new breakthroughs in treatment for these “invisible wounds of war" and help to improve the lives of service members, veterans, and their families.
Home Base Program clinicians are researching new therapies to better diagnose and treat Post Traumatic Stress (PTSD) and Traumatic Brain Injury (TBI). Your Home Base clinician can discuss possible research studies with you. If you are interested, they will work with you to see which study would be the best fit for you.*
Home Base affiliated research studies at Massachusetts General Hospital and Spaulding Rehabilitation Hospital include:
For general questions about research at Home Base, contact Rebecca Zakarian at email@example.com, (617) 643-8973
*Compensation for time and travel may be available.
If you answered "yes" to ANY of these questions, you may be eligible for a Home Base research study of Post Traumatic Stress. Participants receive therapy or study medication at no cost.
To learn more about the study, listen to this WBUR radio story, entitled: New PTSD Study Offering Hope To Veterans. For information call 1-617-726-1579 or email firstname.lastname@example.org.
All inquiries are kept confidential. Compensation up to $375 provided for study participants.
• What: This study is comparing 3 treatments for posttraumatic stress disorder, each shown to be effective for PTSD. The treatments are a talk therapy (Prolonged Exposure; PE), a medication (sertraline), and the combination of the two.
• When: 12 weeks of treatment, followed by 12 weeks of less frequent visits and a 1-year follow-up visit
• Who: OEF/OIF/OND veterans or active duty service members who have had combat-related posttraumatic stress symptoms for at least three months
• Compensation: Individuals receive $50 for each assessment, for up to $300. Individuals receive an additional $800 if they choose to do the optional fMRI scan that occurs in Ann Arbor, MI.
• Where: Massachusetts General Hospital (Boston, MA)
• Contact: Benjamin Kovachy, email@example.com, 617-726-0666; Andrew Rogers, firstname.lastname@example.org, 617-726-1579
• What: This study uses fMRI and PET scans to examine brain activity in individuals who have PTSD and to predict their response to cognitive behavioral therapy
• When: One fMRI scan before therapy and two optional PET scans before and after therapy
• Who: Participants must be ready to receive cognitive behavioral therapy through Dr. Naomi Simon’s clinic at the Massachusetts General Hospital
• Compensation: $50 for the fMRI scan and $75 for each optional PET scan
• Where: The Massachusetts General Hospital (Charlestown, MA)
• Contact: Lisa M. Shin, PhD: email@example.com or (617) 726-8120
• What: This study is comparing four treatments for complicated grief. The treatments are a talk therapy for complicated grief (CGT) and a medication (citalopram), CGT and a pill placebo, citalopram alone, or pill placebo alone.
• When: 16 to 20 weeks of treatment with 3 months of follow-up treatment and a 6-month follow up visit
• Who: Individuals who lost a loved one over 6 months ago and are feeling stuck in their grief
• Compensation: $110-200
• Where: Massachusetts General Hospital (Boston, MA)
• Contact: Arielle Horenstein, firstname.lastname@example.org, 617-726-4585
• What: The research study examines the benefits of transcranial direct current stimulation on memory
• When: 3 visits that last approximately 2 hours each, that are scheduled at least 48 hours apart, at times that are convenient for the participant
• Who: 2 groups: one group of individuals who are 19 years or older and had a traumatic brain injury at least 1 year ago; and one group of individuals who are 19 years or older who have not had a traumatic brain injury
• Compensation: $25 grocery card at the end of each of the 3 study visits
• Where: Spaulding Rehabilitation Hospital (Charlestown, MA)
• Contact: Therese O’Neil-Pirozzi, 617-373-5750, email@example.com
• What: This research will examine potential differences between individuals diagnosed with PTSD plus mild traumatic brain injury compared to individuals diagnosed with PTSD only in their response to a type of talk therapy called cognitive processing therapy (CPT).
• When: 12 weeks of treatment at the Home Base Program, a 6-month follow-up, and completing a MRI, clinical symptom scales, and neurocognitive assessments
• Who: OEF/OIF/OND veterans 50 years or younger who have been diagnosed with PTD and who do or do not have mild traumatic brain injury
• Compensation: up to $300
• Where: Massachusetts General Hospital (Boston, MA)
• Contact: Karen Chen, firstname.lastname@example.org, 617-724-2767
• What: Study Description: The purpose of this research study is to find out more about how the human brain forms and stores emotional memory. In particular, we would like to understand how human beings learn not to fear. We hope this study will help us understand why people with anxiety disorders cannot control unwanted fear. If eligible for this study, you will have two fMRI scans, during which you will perform some small tasks, such as finger tapping, while the MRI makes detailed pictures (images) of your brain.
• When: 3 separate visits for a total of 7 hours
• Who: You may be eligible if:
o You are currently suffering from generalized social anxiety disorder, panic disorder, or a specific phobia.
o You are between 18 and 65 years of age.
o You are right-handed.
o You have normal (or corrected) vision.
o You have been on stable psychotropic medications for at least 8 weeks and are not currently taking benzodiazepines.
o You do not have any metal in your body.
• Compensation: Up to $230
• Where: Massachusetts General Hospital, Charlestown Navy Yard
• Contact: Allie Campbell, (617) 726-3508, email@example.com
Dr. Jerrold F. Rosenbaum, Psychiatrist-in-Chief at the Massachusetts General Hospital and Stanley Cobb Professor of Psychiatry at Harvard Medical School, is the head of the Home Base Program’s scientific council for research.
Dr. Rosenbaum is recognized as one of the world’s authorities on mood and anxiety disorders. His research contributions include extensive leadership in the development of new therapies, the design and implementation of trials to develop innovative treatments for major depression, treatment resistant depression, and panic disorder, studies of psychopathology including comorbidity and subtypes, and studies of longitudinal course and outcomes of those disorders.
At Mass General, Dr. Rosenbaum directs a department of more than 600 clinicians, researchers, and trainees, named by U.S. News and World Report as the #1 Department of Psychiatry in the United States for 16 of the last 18 years. Also at Mass General – the largest hospital based research institution in the world, with over 700 million dollars per year of research funding – he served as Chair of the hospital’s Executive Committee on Research. His clinical and consulting practice specializes in treatment resistant mood and anxiety disorders, and he consults extensively to colleagues on management of these conditions.
Dr. Rosenbaum was the 2007 recipient of the C. Charles Burlingame Award given annually for lifetime achievement in psychiatric research and education by the Institute of Living in Hartford, CT, and the 2011 Massachusetts Association of Mental Health Friend and Leader Award. He served as President and the Chairman of the Board of the Anxiety and Depression Association of America and is Chair of the Scientific Council and on the Board of Directors for the American Foundation for Suicide Prevention. He also serves on the MGH Board of Trustees. He and colleagues have recently founded a venture, PsyBrain, for the discovery and development of novel therapeutics for psychiatric disorders.
Dr. Rosenbaum received his undergraduate degree from Yale College and his medical degree from Yale School of Medicine. He completed his residency and fellowship in Psychiatry at Mass General, Harvard Medical School.
Amar Sahay, Ph.D, is an Assistant Professor of Psychiatry at Harvard Medical School, Massachusetts General Hospital, Center for Regenerative Medicine, and Principal faculty at the Harvard Stem Cell Institute. His primary research interests include how plasticity mechanisms in the adult brain affect cognition and mood and how perturbations in neural circuits may contribute to psychiatric disorders. Among other honors, Dr. Sahay has been the recipient of the Society for Neuroscience Career Development Award, the NIMH Pathway to Independence Award, and the Ellison New Scholar Award. StemBook Editor, Lisa Girard, was able to talk with Dr. Sahay recently about the exciting advances in understanding how changes in neural circuitry, specifically adult hippocampal neurogenesis, affects cognition and mood.
The Sahay lab is interested in understanding how new brain cells can be harnessed to regulate fear. Recent studies have overturned the century old dogma that the adult brain cannot generate new brain cells. Remarkably, stem cells in a part of the brain called the “hippocampus” that is essential for formation of new memories of places and events generates new brain cells everyday. We recently proposed that the overgeneralization of fear seen in patients with PTSD may arise from an inability of the hippocampus to distinguish between similar places or features and this results in the retrieval of previously experienced aversive or traumatic memories. Importantly, our work has shown that stimulating the capacity to make new brain cells in rodents dampens overgeneralization of fear. We are currently exploring (i) how these new brain cells exert their effects on regulation of fear, (ii) how stress, a known risk factor for PTSD, affects brain circuits underlying fear generalization, and (iii) how genes modulate overgeneralization of fear. Since the brain circuits of the hippocampus of mice and men are similar, we hope that these studies will lead to new therapeutic strategies for treating overgeneralization of fear in patients with PTSD.
To learn more about these research studies visit http://www.massgeneral.org/regenmed/staff/researchlab.aspx?id=1473.
Massachusetts General Hospital (MGH) and Spaulding Rehabilitation Hospital doctors and researchers are working to develop better treatments for post traumatic stress disorder (PTSD) and traumatic brain injury (TBI). This research may lead to new breakthroughs in treatment for these conditions and help to improve the lives of service members and veterans.
MGH has a long tradition of being a leader in medical discoveries. In 1846, MGH was the first hospital to use anesthesia for surgery. In 2008, MGH developed a device—the size of a credit card—to detect small amounts of cancer cells in the blood stream.
Every day, researchers at MGH take basic scientific discoveries and transform clinical patient care. Almost every treatment, test, drug, or medical device used today is the result of research and the willingness of individuals to participate in order to advance medical care for others.
Five important facts about research at Home Base, Massachusetts General Hospital and Spaulding Rehabilitation Hospital:
Phone: (617) 724-5202
Home Base Program